Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Pharmaceutical Business ReviewAuvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication.NeuroscienceRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: LEO Pharma to acquire gene therapy company ReplayNext: FDA’s ODAC delivers one loss, one win for AstraZeneca Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
